Literature DB >> 3278517

Clinical course and electrophysiology of multiple sclerosis.

S G Waxman1.   

Abstract

Entities:  

Mesh:

Year:  1988        PMID: 3278517

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


× No keyword cloud information.
  7 in total

1.  Activity-dependent hyperpolarization of human motor axons produced by natural activity.

Authors:  R Vagg; I Mogyoros; M C Kiernan; D Burke
Journal:  J Physiol       Date:  1998-03-15       Impact factor: 5.182

2.  Are VEP abnormalities in optic neuritis (ON) dependent on plaque size? A reappraisal of the physiopathology of ON based on improved MRI and multiple-lead recordings.

Authors:  T Fulgente; A Thomas; L Lobefalo; L Mastropasqua; P E Gallenga; D Gambi; M Onofrj
Journal:  Ital J Neurol Sci       Date:  1996-02

3.  Evoked potential (EP) alterations in experimental allergic encephalomyelitis (EAE): early delays and latency reductions without plaques.

Authors:  D Gambi; T Fulgente; D Melchionda; M Onofrj
Journal:  Ital J Neurol Sci       Date:  1996-02

4.  Direct demonstration of reduction of the output of the human motor cortex induced by a fatiguing muscle contraction.

Authors:  V Di Lazzaro; A Oliviero; P A Tonali; P Mazzone; A Insola; F Pilato; E Saturno; M Dileone; J C Rothwell
Journal:  Exp Brain Res       Date:  2003-03-08       Impact factor: 1.972

5.  Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment.

Authors:  L La Mantia; F Riti; C Milanese; A Salmaggi; M Eoli; C Ciano; G Avanzini
Journal:  Ital J Neurol Sci       Date:  1994-10

6.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.

Authors:  K Gijbels; R E Galardy; L Steinman
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

Review 7.  A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS.

Authors:  Martin Hardmeier; Letizia Leocani; Peter Fuhr
Journal:  Mult Scler       Date:  2017-05-08       Impact factor: 6.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.